organization · Reporting owner

ACORN CAPITAL ADVISORS GP, LLC

Disclosed activity across 1 company

Tapewire entity: 79604
SEC CIK: 0001813692

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
OnKure Therapeutics, Inc.OKUR · Entity 6550	10% owner	May 15, 2025	May 19, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

OnKure Therapeutics, Inc.

Report date May 15, 2025 · Filed May 19, 2025

Jointly reported with ACORN BIOVENTURES, L.P., Hove Anders D

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,709,944	Reported balance After 2025-05-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-05-15 · Purchase · Acquired 270,270 · Balance 1,709,944 F1: Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Acorn Bioventures 2, L.P.	1,129,730	Reported balance After 2025-05-15 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-05-15 · Purchase · Acquired 1,129,730 · Balance 1,129,730 F2: Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F2: Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 15, 2025 Filed May 19, 2025 16:43 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	PurchaseCommon Stock	1,129,730	$1.85	$2,090,000.50	Disclosure SEC source: 0000950170-25-074459 · ownership.xml · nonDerivative · entry 2 ACORN BIOVENTURES, L.P. · CIK 0001766853 · 10% owner ACORN CAPITAL ADVISORS GP, LLC · CIK 0001813692 · 10% owner Hove Anders D · CIK 0001365618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Acorn Bioventures 2, L.P. Disclosed balance after: 1,129,730 F2 · ownership.direct: Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document
May 15, 2025 Filed May 19, 2025 16:43 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	PurchaseCommon Stock	270,270	$1.85	$499,999.50	Disclosure SEC source: 0000950170-25-074459 · ownership.xml · nonDerivative · entry 1 ACORN BIOVENTURES, L.P. · CIK 0001766853 · 10% owner ACORN CAPITAL ADVISORS GP, LLC · CIK 0001813692 · 10% owner Hove Anders D · CIK 0001365618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,709,944 F1 · ownership.direct: Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.